The U.S. Securities and Exchange Commission announced Thursday that the former business chief of Osiris Therapeutics Inc. has agreed to pay $40,000 to exit a case accusing him and other executives of duping an auditor into allowing the biotech company to book fake revenue…

Read this piece in its entirety at Law360.